854306-67-5

Upstream product

• 67-56-1 methanol 
• 40546-94-9 6-methyl-4-phenyl-3,4-dihydrocoumarin 
• 100-39-0 benzyl bromide 
• 106-44-5 p-cresol 
• 140-10-3 (E)-3-phenylacrylic acid 

Downstream Products

• 207679-81-0 (R)-2-[3-(diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)-phenol 
• 389068-22-8 N,N-diisopropyl-3-(2-benzyloxy-5-methylphenyl)-3-phenylpropylamine 
• 286930-02-7 fesoterodine 
• 286930-03-8 fesoterodine fumarate 
• 214601-54-4 (R)-[4-benzyloxy-3-(3-diisopropylamino-1-phenyl-propyl)-phenyl]-methanal 
• 1373556-77-4 N,N-diisopropyl-3-(2-benzyloxy-5-methyl-phenyl)-3-phenyl-propane amide 
• 124936-74-9 N,N-diiso-propyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine 
• 124937-52-6 tolterodine tartrate 
• 848768-06-9 (R)-3-[2-(benzyloxy)-5-methylphenyl]-N,N-diisopropyl-3-phenylpropan-1-amine 
• 156755-37-2 {4-(benzyloxy)-3-[(1R)-3-(dipropan-2-ylamino)-1-phenylpropyl]phenyl}methanol 

Relevant academic research and scientific papers

Ligand-Phospholipid Conjugation: A Versatile Strategy for Developing Long-Acting Ligands That Bind to Membrane Proteins by Restricting the Subcellular Localization of the Ligand

We hypothesized that if drug localization can be restricted to a particular subcellular domain where their target proteins reside, the drugs could bind to their target proteins without being metabolized and/or excreted, which would significantly extend the half-life of the corresponding drug-target complex. Thus, we designed ligand-phospholipid conjugates in which the ligand is conjugated with a phospholipid through a polyethylene glycol linker to restrict the subcellular localization of the ligand in the vicinity of the lipid bilayer. Here, we present the design, synthesis, pharmacological activity, and binding mode analysis of ligand-phospholipid conjugates with muscarinic acetylcholine receptors as the target proteins. These results demonstrate that ligand-phospholipid conjugation can be a versatile strategy for developing long-acting ligands that bind to membrane proteins in drug discovery.

A PROCESS FOR PREPARING FESOTERODINE

The present invention relates to an improved process for the preparation of Fesoterodine and pharmaceutically acceptable salts thereof. The present invention particularly relates to a process for the preparation of fesoterodine and pharmaceutically acceptable salts thereof which involves use and preparation of R(+) benzyl tolterodine and fumarate salt of R(+)-[4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-phenyl]-methanol.

Process for preparing tolterodine

A process for preparing tolterodine with high purity.

An improved, scalable, and impurity-free process for tolterodine tartrate

Tolterodine tartrate is an anticholinergic muscle relaxant used to treat urinary frequency, urinary urgency, and incontinence in people with unstable bladders. An improved, cost-effective, and impurity-free process for tolterodine tartrate suitable for la